Wenjing Gu

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Journal: Haematologica

Published: June 01, 2026

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

Journal: British journal of haematology

Published: April 16, 2026

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Journal: British journal of haematology

Published: February 24, 2026

Isavuconazole therapeutic drug monitoring in real-world clinical practice: an age-stratified analysis of determinants.

Isavuconazole therapeutic drug monitoring in real-world clinical practice: an age-stratified analysis of determinants.

Journal: Frontiers in pharmacology

Published: January 01, 2026

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Journal: Annals of hematology

Published: November 25, 2025

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: November 05, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: August 25, 2025

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: March 24, 2025

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: June 20, 2024

Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.

Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms.

Journal: Haematologica

Published: June 19, 2024

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.

Journal: Leukemia

Published: June 18, 2024

Showing 1-12 of 20

Last Updated: 09/26/2026